SERUM INSTITUTE OF INDIA
India is amongst the top 12 preferred biotech destinations in the world and third largest biotechnology destination in the Asia Pacific region.
Serum Institute of India Pvt. Ltd. manufactures several vaccines, which include Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. 65% of children in the world are estimated to receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization.
- Founded in 1966 with the aim to manufacture immune biologicals, which were short in India and imported at higher prices.
- Manufactures life-saving biologicals at affordable prices.
- Serum vaccines are used in ~170 countries in their national immunisation programmes.
Serum Institute of India – Protection from birth onwards
| Year | Milestone |
|---|---|
| 2022 |
In September 2022, India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine 'CERVAVAC' was announced for the prevention of cervical cancer. Serum Institute of India (SII) plans to launch the country’s first indigenous HPV vaccine to combat cervical cancer in the near future. |
| 2021 |
In December 2021, Serum Institute of India pledged US$ 66.2 million to the University of Oxford to setup a research campus. In November 2021, Serum Institute of India crossed the 1 billion doses of Covishield vaccine production milestone. Serum Institute Life Sciences Private Limited (SILS) and Biocon Biologics Limited (BBL) announced a strategic alliance to develop antibodies for infectious diseases such as dengue, HIV, and others. In June 2021, SII announced plans to launch Novavax's COVID-19 vaccine 'Covovax' in India by September 2021 Government of India signed a deal to procure 20 million doses of its COVID-19 vaccination. |
| 2020 |
Launched India’s first fully indigenously developed pneumococcal vaccine, 'Pneumosil' |
| 2016 |
Launched world’s first rabies human monoclonal antibody, recombinant |
| 2014 |
Launched oral polio vaccine |
| 2012 |
Acquired Bilthoven Biologicals, Netherlands Launched Trivalent seasonal influenza vaccine |
| 2011 |
Launched injectable inactivated polio vaccine |
| 2010 |
Launched H1N1 influenza vaccine |
| 2009 |
Launched liquid pentavalent vaccine (DPT-HepB-Hib) (PENAVAC SD/PFS) |
| 2007 |
Launched Hib vaccine and BCG vaccine for bladder cancer |
| 2002 |
Launched BCG vaccine |
| 2001 |
Launched Hepatitis B vaccine |
| 1993 |
Launched MMR vaccine |
| 1989 |
Launched measles vaccine |
| 1974 |
Commenced production of DTP vaccine |
Partners
